Filing Details

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13D/A
Amendment No. 5

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND
AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a)

Summit Therapeutics PLC

(Name of Issuer)

American Depositary Shares and Ordinary Shares, par value £0.01 per share

(Title of Class of Securities)

86627R102

(CUSIP Number)

Hugh Orange

c/o Lansdowne Partners (UK) LLP

15 Davies Street

London W1K 3AG

England

44-20-7290-5500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

March 23, 2020

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D/A, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in the cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No.

86627R102

 

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Lansdowne Partners (UK) LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) [_]
		(b) [_]
3.	SEC USE ONLY
4.	SOURCE OF FUNDS
	AF
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	[_]
6.	CITIZENSHIP OR PLACE OF ORGANIZATION
	England
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7.	SOLE VOTING POWER
	0
8.	SHARED VOTING POWER
	21,143,500[1]
9.	SOLE DISPOSITIVE POWER
	0
10.	SHARED DISPOSITIVE POWER
	21,143,5001
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	21,143,5001
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	[_]
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	6.30%
14.	TYPE OF REPORTING PERSON
	IA

_____________________

^[1] The 21,143,500 Ordinary Shares beneficially owned consist of 4,228,700 American Depositary Shares, which may be exchanged for Ordinary Shares at a 1:5 ratio.

 

CUSIP No.

86627R102

 

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Lansdowne Developed Markets Master Fund Limited
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) [_]
		(b) [_]
3.	SEC USE ONLY
4.	SOURCE OF FUNDS
	WC
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	[_]
6.	CITIZENSHIP OR PLACE OF ORGANIZATION
	Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7.	SOLE VOTING POWER
	0
8.	SHARED VOTING POWER
	21,143,500[2]
9.	SOLE DISPOSITIVE POWER
	0
10.	SHARED DISPOSITIVE POWER
	21,143,5002
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	21,143,5002
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	[_]
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	6.30%
14.	TYPE OF REPORTING PERSON
	CO

_____________________

^[2] The 21,143,500 Ordinary Shares beneficially owned consist of 4,228,700 American Depositary Shares, which may be exchanged for Ordinary Shares at a 1:5 ratio.

 

CUSIP No. 86627R102

13D/A

 

Statement on Schedule 13D/A

 

ITEM 1.

SECURITY AND ISSUER.

This statement on Schedule 13D/A (the "Schedule 13D/A") relates to the Ordinary Shares, par value £0.01 per share (the "Ordinary Shares") and the American Depositary Shares, each representing five Ordinary Shares (the “ADSs” and together with the Ordinary Shares, the “Shares”), of Summit Therapeutics PLC, a foreign private issuer incorporated in England and Wales whose principal executive office is located at 136A Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, United Kingdom (the "Issuer").

ITEM 2.

IDENTITY AND BACKGROUND.

(a-c, f) This Schedule 13D/A is being filed on behalf of: (i) Lansdowne Partners (UK) LLP, an English limited liability partnership ("Lansdowne") and (ii) Lansdowne Developed Markets Master Fund Limited, a Cayman Islands exempted company (the "Fund" and together with Lansdowne, the “Reporting Persons”). The Fund is a privately offered investment fund that holds the Shares reported in this Schedule 13D/A. Lansdowne is the investment adviser to the Fund and as a result is the beneficial owner of the Shares reported in this Schedule 13D/A.

The principal business address of Lansdowne is 15 Davies Street, London W1K 3AG, England and the principal business address of the Fund is c/o BNP Paribas Fund Administration Services, 2 Grand Canal Plaza, Grand Canal Street, Dublin 2, Ireland.

(d)       None of the Reporting Persons, individually or collectively, has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)       None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

ITEM 3.

SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

The funds for the purchase of the Shares beneficially owned by the Reporting Persons came from the working capital of the Fund. The total cost for the Ordinary Shares previously beneficially owned by the Reporting Persons and subsequently converted to ADS is £15,778,040 and the total cost for the additional ADSs beneficially owned by the Reporting Persons is $17,206,992. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes (including certain leverage arrangements) in the ordinary course of business.

ITEM 4.

PURPOSE OF TRANSACTION.

The Reporting Persons hold the securities described in Item 5 of this statement for investment purposes only.

The Reporting Persons have no plan or proposal which relates to, or would result in, any of the actions enumerated in Item 4 of the instructions to Schedule 13D/A.

 

ITEM 5.

INTEREST IN SECURITIES OF THE ISSUER.

(a - e) Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.

In connection with the Ordinary Shares ceasing to be admitted to trading on AIM, all Ordinary Shares have been converted to ADSs with a settlement date of March 23, 2020. There have been no other transactions by the Reporting Persons in the Shares during the past sixty days.

ITEM 6.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

None

ITEM 7.

MATERIAL TO BE FILED AS EXHIBITS.

Exhibit A Joint Filing Agreement

Exhibit B Schedule of Transactions in Shares

 

CUSIP No. 86627R102

13D/A

 

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 26, 2020

Lansdowne Partners (UK) LLP		/s/ Hugh Orange
		Signature
		Hugh Orange
		Chief Compliance Officer
Lansdowne Developed Markets Master Fund Limited		/s/ Hugh Orange
		Signature
		Hugh Orange
		Chief Compliance Officer of its investment adviser

 

Exhibit A

 

AGREEMENT

 

The undersigned agree that this Schedule 13D/A, dated March 26, 2020, relating to the Ordinary Shares, par value £0.01 per share and the American Depositary Shares, each representing five Ordinary Shares, of Summit Therapeutics PLC shall be filed on behalf of the undersigned.

Date: March 26, 2020

Lansdowne Partners (UK) LLP		/s/ Hugh Orange
		Signature
		Hugh Orange
		Chief Compliance Officer
Lansdowne Developed Markets Master Fund Limited		/s/ Hugh Orange
		Signature
		Hugh Orange
		Chief Compliance Officer of its investment adviser